Journal of Nanomedicine & Nanotechnology

Ocular application of dirithromycin with chitosan based polymeric nanoparticles

4^th International Conference on Nanotek & Expo

December 01-03, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Ebru Basaran, Evrim Y Enilmez, G?lsel Yurtdaş Kırımlıoglu and Yasemin Yazan

Scientific Tracks Abstracts: J Nanomed Nanotechnol

Abstract:

Dirithromycin belongs to the new generation of the macrolide antibiotic family. It is more powerful and shows longer efficacy with much shorter treatment period than erythromycin. Treatment of ocular bacterial infections remains problematic because of thelimited ocular bioavailability of active agents. Due to the characteristic properties of the eye (normal tear turnover, nasolacrimal drainage, cornea?s barrier effect etc.) efficacy of the treatment mostly remains insufficient. Therefore main approaches for the enhancement of ocular bioavailability of the formulations applied are enhancement of the residence time of the active material at the site of action or enhancement of the ocular penetration of the primary penetration site. Chitosan has attracted a lot of attention in ocular applications as a potential penetration enhancer across the mucosal epithelia due to its polycationic, biocompatible and biodegradable nature together with its mucoadhesive property. Therefore in this study, polymeric nanoparticles originated from Chitosan were formulated for the enhancement of ocular bioavailability of Dirithromycin for the sufficient treatment of common bacterial infections.

Biography :

Ebru Basaran got her MSc on ?Sunscreens (Cosmetics)? in 2003 and she had completed her PhD study on ?Controlled Drug Delivery Systems? in 2007. Since 2007 she has been working as an Assistant Professor at the Department of Pharmaceutical Technology at Anadolu University. She was entitled for scholarships by Deutscher Akademischer Austausch Dienst (DAAD) and Academic Exchange Grant by ERASMUS. She was awarded with ?Best Research Study Award? by Nagai Foundation. She has several publications and presentations about ?Controlled Drug Delivery Systems for Ocular Applications?. She also contributes to Pharmaceutical Journals as an active reviewer.